Fractional exhaled nitric oxide in respiratory diseases
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Fractional exhaled nitric oxide (FeNO) is a simple, sensitive and non-invasive marker that can monitor eosinophilic airway inflammation. Its levels are influenced by height, weight, gender, ethnicity and smoking status. FeNO was first introduced as a biomarker to assist in asthma detection, and now plays an important auxiliary role in its diagnosis, management, and prognosis evaluation, including treatment guidance and drug efficacy assessment. With continuous exploration, exhaled nitric oxide has demonstrated utility in a variety of respiratory diseases, including chronic obstructive pulmonary disease, chronic cough and interstitial lung disease. It can also serve as a biomarker after lung surgery to indicate the risk of postoperative complications and impaired lung function. This article summarizes the clinical value of exhaled nitric oxide in common pulmonary diseases, aiming to provide a reference for its clinical application.
Fields of Study & Subjects
Asthma and respiratory diseases
Chronic Obstructive Pulmonary Disease (COPD) Research
Sinusitis and nasal conditions
Publication details
- Journal / source
- Perioperative Precision Medicine
- Volume
- 4
- Issue
- 1
- Pages
- 44–56
- Publication date
- 31 March 2026
- Language
- EN